Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance

Written by Petra Hegmann on 14th January 2019. Posted in Client News.

• Previous
• Next